Reclast is the brand name for a 5 mg intravenous dose of zoledronic acid given once a year for osteoporosis. It is the only bisphosphonate you cannot pick up at a pharmacy counter, which means it arrives as two separate charges instead of one: the drug, and the appointment where somebody hangs the bag.
That split is the entire story of what it costs. The drug has been generic for years and is now genuinely cheap. The administration is not, and it varies by a factor of more than three depending on which building you walk into. Everything below was researched on September 3, 2026.
What Does Reclast Cost Without Insurance?
Federal figures come from the CMS Medicare Part B payment limit file effective July 1 through September 30, 2026, the 2026 Physician Fee Schedule relative value file, the July 2026 hospital outpatient addendum, and CMS acquisition-cost data effective August 19, 2026. Cash prices come from Drugs.com and Sage Infusion, both read September 3, 2026.
| Reclast / zoledronic acid 5 mg cost item | Low | Typical | High |
|---|---|---|---|
| The drug alone, one 5 mg / 100 mL bag | $16.81 (Medicare allowance) | $47.74 (CMS acquisition cost) | $146.54 (retail cash) |
| Brand-name Reclast, one bag | $1,286.58 | $1,286.58 | $1,286.58 |
| Infusion administration alone, CPT 96365, Medicare rates | $67.14 (physician office) | $67.14 (physician office) | $217.31 (hospital outpatient) |
| Whole visit, drug plus infusion | $83.95 (Medicare, office) | $95.15 (published cash price) | $217.31 (Medicare, hospital outpatient) |
| Actual 2024 Medicare spending per claim, drug only | $29.03 | $29.03 | $29.03 |
| Medicare 20% coinsurance, if you have Part B | $3.36 (drug) | $13.43 (office infusion) | $43.47 (hospital infusion) |
The arithmetic is worth doing yourself because it is unusually simple. Medicare’s July 2026 Part B payment limit for HCPCS J3489 is $3.361 per milligram of zoledronic acid, so a 5 mg Reclast dose is $16.81 of drug. CMS acquisition data prices the generic 5 mg / 100 mL bag at $0.47740 per milliliter, or $47.74 for a full bag, and Drugs.com lists the same bag at $49.25 to $146.54 for a cash buyer. Two independent federal and commercial sources put the drug somewhere between $17 and $50 for most buyers.
For a reality check on what actually gets billed, CMS Medicare Part B spending data for 2024 shows average Medicare spending of $29.03 per claim across 143,810 claims and 96,550 beneficiaries, on $4.18 million of total spending. That code covers both the 5 mg osteoporosis dose and the 4 mg oncology dose, so it is a blended figure, but it confirms the drug side is a two-figure number. CMS also records the average price per milligram falling 24.9% between 2023 and 2024.
The administration is the bigger bill, and it depends on the building
Somebody has to start the IV and run it, which is billed separately under CPT 96365, the code for the first hour of a therapeutic intravenous infusion. Medicare pays for that code twice over, at two very different rates.
In a physician office, the 2026 Physician Fee Schedule assigns 96365 a total of 2.01 non-facility relative value units, which at the $33.4009 conversion factor comes to $67.14. In a hospital outpatient department, the July 2026 outpatient addendum pays the same code $217.31 under ambulatory payment classification 5693, with a minimum patient copayment of $43.47. Identical work, 3.2 times the money, decided entirely by which entity owns the chair.
Note also that the drug carries status indicator N in the hospital outpatient system, meaning it is packaged into that $217.31 rather than paid separately. So a hospital visit is not $217 plus the drug. It is $217 with the drug swallowed into it, at Medicare rates.
A self-pay clinic is not bound by any of these numbers. It can charge less or considerably more. Sage Infusion, a national infusion-center chain that publishes its cash prices, lists $95.15 per Reclast visit with $0.00 in extra fees, which is within about $11 of the Medicare office math. That is a useful benchmark to quote when you call around.
What Drives the Price
Generic versus brand. Drugs.com lists brand Reclast at $1,286.58 for one 5 mg / 100 mL bag and the generic at $49.25 for the same thing. That is 26 times the money for the identical molecule at the identical strength. Brand Reclast is still an approved, marketed product under Sandoz, so a clinic can order it, but there is no cash-payer reason to.
Site of care. This is the single biggest lever you control. Medicare’s own two fee schedules price the same infusion at $67.14 in a physician office and $217.31 in a hospital outpatient department. Commercial and self-pay spreads between those two settings are usually wider than Medicare’s, not narrower.
Whether an office visit gets billed too. Many practices bill an evaluation and management visit alongside the infusion. That is a separate line worth asking about before you book.
Your dosing interval. The FDA label revised February 2026 specifies 5 mg once a year for treatment of postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced osteoporosis, and 5 mg once every two years for prevention. A prevention patient pays this bill half as often.
Lab work and monitoring. The label requires patients be appropriately hydrated and, for kidney function, that renal status be evaluated. Any labs your prescriber orders are their own bill.
Cash Price vs. Insurance
Reclast is billed under the medical benefit, not the pharmacy benefit, so a discount card does nothing here. There is no pharmacy counter to shop and no coupon to stack. What you are negotiating is a clinic’s price for a visit.
That is unusual good news for a cash payer. Because the drug is generic and cheap, the total is small enough that self-pay is often genuinely competitive with running it through a deductible. If you have a high-deductible plan and have not met the deductible, you may pay the full negotiated rate anyway, which can easily exceed a published $95 cash price at an independent infusion center.
For traditional Medicare, Part B covers it and the standard 20% coinsurance applies: about $3.36 on the drug and $13.43 on an office infusion, or $43.47 on a hospital outpatient infusion at the published minimum copayment. Those figures assume the Part B deductible is already met.
The trap to avoid is the hospital outpatient department. If your prescriber’s health system routes you there by default, the same infusion generates a facility bill on top of everything else, and gross charges on a hospital chargemaster bear no relationship to the $217.31 Medicare allows. Pull the facility’s posted rates first using our guide to hospital price transparency, and if a bill arrives that looks nothing like the quote, our fair price checker will tell you how far off it is.
How to Pay Less
-
Ask for an independent infusion center or a physician office, not a hospital. This is worth more than every other tactic combined. Medicare’s own data says the identical infusion is priced at $67.14 in an office and $217.31 in a hospital outpatient department, and self-pay spreads run wider. Call at least two non-hospital sites before you book.
-
Get the quote itemized into three numbers before you schedule. Drug, infusion administration, and office visit. Ask specifically whether generic zoledronic acid or brand Reclast will be used, because that single answer is the difference between roughly $49 and $1,287.
-
Quote a published cash price back at them. Sage Infusion publishes $95.15 per Reclast visit with no extra fees. Naming a real, published number from a real seller is the most effective opening in any self-pay conversation. Our negotiation script covers how to phrase it, and our guide to negotiating medical bills covers what to do if the bill arrives higher than the quote anyway.
-
Apply for charity care if a health system does the billing. Nonprofit hospitals are required to have a written financial assistance policy, and infusion visits qualify like any other outpatient service. Start with hospital charity care and our charity care checker.
-
Price the pill alternative honestly. A full year of generic oral alendronate runs about $72 to $136 as a cash payer, which is less than the $217.31 Medicare pays a hospital just to run the IV. Our alendronate cost guide has the full oral pricing. Which one is appropriate for you is a clinical question, not a budget one, but you should know the numbers before that conversation.
-
Handle the prescribing and monitoring cheaply. A free or sliding-scale clinic can manage the prescription, the labs, and the follow-up, which is often the quietly recurring cost of staying on any osteoporosis drug. A cash-pay DEXA scan is its own separate bill worth pricing in advance.
Bottom Line
Budget roughly $85 to $220 for a Reclast infusion, once a year, and treat anything into the four figures as a signal that you are either being quoted brand-name drug or being sent to a hospital outpatient department. The published cash benchmark to beat is $95.15 for the whole visit.
On a per-year basis this is one of the cheapest real osteoporosis treatments available to a cash payer, and it is not close. The same infusion chain that charges $95.15 for Reclast charges $2,004.74 per Prolia visit and $2,959.16 per Evenity visit, and the anabolic injectables Forteo and Tymlos are daily self-injections with their own pricing entirely. Only the cheap oral generics, led by alendronate, come in lower. If you got here after a fracture, our hip replacement cost guide covers the expense this whole category exists to prevent.